STOCK TITAN

Iveda Solutions may sell up to $1.37M in common stock

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B5

Rhea-AI Filing Summary

Iveda Solutions, Inc. (IVDA) may currently offer and sell additional common stock through or to H.C. Wainwright & Co., acting as sales agent or principal, for an aggregate offering price of up to $1,368,350 under its at-the-market program. The company says it did not offer and sell shares under the Form S-3 public-float provision during the 12-calendar-month period ending November 20, 2026.

While Iveda’s public float remains below $75 million, public primary offerings under that provision may not exceed one-third of public float in any 12-calendar-month period. Iveda’s public float was approximately $4,105,052 as of November 18, 2026, based on 13,242,102 shares held by non-affiliates and a $0.31 closing sale price on September 23, 2026. If the float increases enough to permit additional sales, the company says it will file another prospectus-supplement amendment before making them.

Filing Explained

Iveda’s up-to-$1,368,350 ATM capacity is permission to sell, not a completed issuance; if used, the program can sell new shares gradually at prevailing prices, increasing the share count and reducing existing holders’ percentage ownership.

ATM aggregate offering price Up to $1,368,350 Additional common stock Iveda may currently offer and sell through or to H.C. Wainwright & Co.
Public float market value Approximately $4,105,052 As of November 18, 2026
Non-affiliate shares 13,242,102 shares Common stock held by non-affiliates as of November 18, 2026
Closing sale price $0.31 per share Closing sale price on September 23, 2026, used to calculate public float
Public-float threshold $75 million The one-third-of-public-float limit applies while public float remains below this amount
Form S-3 public-primary-offering limit One-third of public float Maximum value in any 12-calendar-month period while public float remains below $75 million
at the market offering financial
"previously announced “at the market offering” program"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
public float financial
"aggregate market value ... or the public float"
Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.
General Instruction I.B.6 of Form S-3 regulatory
"pursuant to General Instruction I.B.6 of Form S-3"
aggregate offering price financial
"having an aggregate offering price of up to $1,368,350"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
Offering Type ATM
Securities Offered Common stock
Offering Amount $1,368,350 aggregate offering price

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much common stock may Iveda Solutions (IVDA) sell through its ATM program?

Iveda may currently offer and sell common stock through or to H.C. Wainwright & Co. for up to $1,368,350 in aggregate offering price under its at-the-market program.

What limit applies to Iveda’s IVDA Form S-3 sales?

While its public float remains below $75 million, public primary offerings on Form S-3 may not exceed one-third of public float in any 12-calendar-month period. If the float increases enough to permit additional sales under the Sales Agreement, Iveda says it will file another prospectus-supplement amendment before making them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

AMENDMENT NO. 1 DATED NOVEMBER 20, 2026

To Prospectus Supplement dated February 27, 2025

(To Prospectus Dated January 24, 2024)

Filed pursuant to Rule 424(b)(5)

Registration No. 333-276676

 

 

IVEDA SOLUTIONS, INC.

 

Up to $1,368,350

Common Stock

 

 

 

This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus, dated January 24, 2024 (the “Prospectus”), and the prospectus supplement, dated February 27, 2025 (the “Prospectus Supplement”), which was filed pursuant to our registration statement on Form S-3 (File No. 333-276676) (the “Registration Statement”). This Amendment should be read in conjunction with the Prospectus and Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus and the Prospectus Supplement. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus and Prospectus Supplement, and any future amendments or supplements thereto.

 

This Amendment is being filed in connection with our previously announced “at the market offering” program, and to update the maximum amount of shares of our common stock, par value $0.00001 per share, that we may issue and sell from time to time through or to H.C. Wainwright & Co., LLC (the “Agent”) as sales agent or principal, pursuant to the terms of our previously announced At the Market Offering Agreement, dated February 27, 2025, between us and the Agent (the “Sales Agreement”).

 

Our common stock is listed on The Nasdaq Capital Market under the symbol “IVDA”. As of November 18, 2026, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was approximately $4,105,052, which was calculated based on 13,242,102 shares of our common stock outstanding held by non-affiliates as of November 18, 2026 at a price of $0.31 per share, the closing sale price for our common stock on September 23, 2026. As of the date hereof, we have not offered and sold any shares of our common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12-calendar month period so long as our public float remains below $75 million.

 

We are filing this Amendment to amend the Prospectus Supplement to update the maximum amount we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. Accordingly, in accordance with the terms of the Sales Agreement, we may currently offer and sell additional shares of common stock through or to the Agent having an aggregate offering price of up to $1,368,350 pursuant to the Prospectus and Prospectus Supplement, as amended by this Amendment. In the event that our public float increases such that we may sell additional amounts under the Sales Agreement, Prospectus and Prospectus Supplement, we will file another amendment to the Prospectus Supplement prior to making additional sales.

 

Investing in our common stock involves risks. You should carefully consider the risks described under “Risk Factors” in the Prospectus and Prospectus Supplement, as well as those described in our other reports and documents we filed with the Securities and Exchange Commission (the “SEC”) that we incorporate by reference in the Prospectus, the Prospectus Supplement and this Amendment, before making a decision to invest in our common stock.

 

Neither the SEC, any state securities commission, nor any other regulatory body has approved or disapproved of these securities or determined if this Amendment is accurate or complete. Any representation to the contrary is a criminal offense.

 

H.C. Wainwright & Co.

 

The date of this Amendment No. 1 to Prospectus Supplement is November 20, 2026.

 

 

 

Keep reading